Vous avez cherché: consider (Finnois - Anglais)

points to consider on missing data
points to consider on missing data

points to consider on adjustment for baseline covariates
points to consider on adjustment for baseline covariates

points to consider on the evaluation of diagnostic agents
points to consider on the evaluation of diagnostic agents

points to consider on multiplicity issues in clinical trials
points to consider on multiplicity issues in clinical trials

points to consider on xenogeneic cell therapy for medicinal products
points to consider on xenogeneic cell therapy for medicinal products

points to consider on the assessment of anti- hiv medicinal products
points to consider on the assessment of anti-hiv medicinal products

points to consider on clinical investigation of medicinal products for treatment of rheumatoid arthritis.
34 emea work programme 2003chapter 1 emea in the european system

points to consider on the evaluation of medicinal products for the treatment of irritable bowel syndrome.
the treatment of irritable bowel syndrome

concept paper on the development of a cpmp points to consider on allergic rhino-conjuctivitis.
points to consider on multiplicity issues in clinical trials.

asiakirjan nimi points to consider on the evaluation of medicinal products for the treatment of irritable bowel syndrome.
note for guidance on clinical investigation of medicinal products for the treatment of migraine

points to consider on quality aspects of medicinal products containing active substances produced by stable transgene experession in higher plants
cpmp position statement on the quality of water used in the production of vaccines for parenteral use

concept paper on the development of a cpmp points to consider on the evaluation of the pharmacokinetics of medicinal products in the paediatric population.
concept paper on the development of a cpmp points to consider on methodological issues in confirmatory clinical trials with flexible design and analysis plan.

concept paper on the development of a cpmp points to consider on methodological issues in confirmatory clinical trials with flexible design and analysis plan.
note for guidance on the clinical investigation of medicinal products in the treatment of asthma note for guidance on clinical investigation of medicinal products for treatment of nociceptive pain concept paper on the development of a cpmp note for guidance on clinical investigation of medicinal products for the treatment of generalised anxiety disorder

asiakirjan nimi compilation of general quality questions answered by the herbal medicinal products working party points to consider on good agricultural and collection practice for starting materials of herbal origin
document titlestatusemea/18123/00emea/hmpwp/31/99 rev 1compilation of general quality questions answered by the herbal medicinal products working party points to consider on good agricultural and collection practice for starting materials of herbal origin

adjustment for multiplicity and related topics points to consider on biostatistical/ methodological issues arising from cpmp discussion on licensing applications:
adjustment for multiplicity and related topics points to consider on biostatistical/ methodological issues arising from cpmp discussion on licensing applications:

choice of non-inferiority margin points to consider on biostatistical/methodological issues arising from cpmp discussion on licensing applications:
design and analysis of confirmatory clinical trialspoints to consider on clinical pharmacokinetic investigation of the pharmacokinetics of peptides and proteins

need for post- marketing data contribution to cpmp points to consider document on xenogeneic cell therapy proposals for revision to standard operating procedure on urgent safety restrictions for medicinal products authorised through the mutual recognition procedure
need for post-marketing data contribution to cpmp points to consider document on xenogeneic cell therapy proposals for revision to standard operating procedure on urgent safety restrictions for medicinal products authorised through the mutual recognition procedure

in this connection , the council will also consider , by the end of 1993 , on the basis of a report , the possibiliry of applying article k. 9 w such matters .
in this connection , the council will also consider , by the end of 1993 , on the basis of a report , the possibiliry of applying article k. 9 w such matters .

muistioissa (points to consider) cpmp esittää näkemyksensä sellaisista lääkevalmisteiden tuotekehittelyn osa - alueista, joista on niukasti kokemusta ja jotka kehittyvät nopeasti.
the number of times on which scientific advice was given in 1998 increased significantly, as industry has recognised the added value given by the cpmp in the early stages of development of their medicinal products.

undertakings or associations referred to in article 48 may , under the same conditions , institute proceedings against decisions o r recommendations concerning them which are individual in character o r against general decisions o r recommendations which they consider to involve a misuse of powers affecting them .
undertakings or associations referred to in article 48 may , under the same conditions , institute proceedings against decisions o r recommendations concerning them which are individual in character o r against general decisions o r recommendations which they consider to involve a misuse of powers affecting them .